1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting

BACKGROUND: Nivolumab (NIV) is a monoclonal antibody for patients with pre-treated advanced nonsquamous non–small-cell lung cancer (NSCLC). It is necessary to evaluate the cost effectiveness of NIV versus docetaxel (DOC), taking into consideration the expression of programmed death ligand 1 (PD-L1)....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur J Hosp Pharm
Päätekijät: Román, AB Fernández, Lázaro, C Bravo, Fernández, J Letellez, Muñoz, N Herrero, Rosado, A Andrés, Lopez, C Mayo, Gutierrez, MDM Garcia, Gil, M Garcia
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Group 2018
Aiheet:
Section 1: Introductory statements and governance
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535427/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia